Skip to main content
Fig. 1 | Trials

Fig. 1

From: Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

Fig. 1

Trial flow diagram. In total 25,210 patients with CKD will be randomised to receive aspirin in addition to their usual medication or no additional treatment (and avoidance of aspirin), and followed up until 1827 adjudicated major cardiovascular events (primary outcome) have occurred. It is anticipated that 3.5 years of recruitment and 2.5 years of follow-up will be required to complete the trial

Back to article page